Did Pfizer buy Arena Pharmaceuticals?
NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases.
Is Arena Pharmaceuticals a good buy?
Valuation metrics show that Arena Pharmaceuticals, Inc. may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of ARNA, demonstrate its potential to underperform the market.
Why did Arena Pharmaceuticals stock drop?
Shares of Arena Pharmaceuticals ( ARNA ) are plummeting today, down by 22% as of 1:35 p.m. EST, after the biotech released data from a mid-stage study of etrasimod in patients with atopic dermatitis, commonly called eczema.
How many employees does Arena Pharmaceuticals have?
By shifting our pipeline focus and realigning our vision, we have grown from less than 130 employees in 2019, to over 400 employees today. As we advance from discovery and development to commercialization, we are building Arena into a long-term, sustainable, and vibrant enterprise.
Who is buying Arna?
Pfizer
Under the terms of the agreement, Pfizer will acquire all the outstanding shares of Arena for $100 per share in an all-cash transaction for a total equity value of approximately $6.7 billion.
What pharmaceutical company did Pfizer just buy?
Arena Pharmaceuticals
Pfizer has agreed to buy U.S. biotech company Arena Pharmaceuticals in a deal valued at about $6.7 billion. The U.S. pharma giant said the acquisition would expand its cancer and inflammatory disease drug pipeline.
Why is ARNA stock going up?
Shares of Arena Pharmaceuticals ( ARNA ) soared 80% on Monday after the drugmaker struck a merger agreement with Pfizer ( PFE -1.60% ).
What stock is Arna?
(ARNA) Latest Stock News & Headlines – Yahoo Finance….Performance Outlook.
| Previous Close | 99.99 |
|---|---|
| 52 Week Range | 45.50 – 100.00 |
| Volume | 0 |
| Avg. Volume | 1,472,638 |
Who is Pfizer merging with?
Mylan
(NYSE: PFE) announced today that it has completed the transaction to spin off its Upjohn Business and combine it with Mylan N.V. to form Viatris Inc. Pfizer Chairman and Chief Executive Officer Dr.
What is Arena Pharmaceuticals known for?
Arena’s portfolio includes diverse and promising development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator currently in development for a range of immuno-inflammatory diseases including …
What do Arena Pharmaceuticals Specialise in?
immuno-inflammatory treatments
Pfizer has entered into an agreement to acquire Arena Pharmaceuticals, a clinical-stage pharma firm specializing in developing immuno-inflammatory treatments, for approximately $6.7b USD.
What company is Pfizer buying?
(NYSE: PFE) and Arena Pharmaceuticals, Inc . (Nasdaq: ARNA) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases.